共 383 条
[1]
Unnikrishnan R(2020)Infections and diabetes: risks and mitigation with reference to India Diabetes MetabSyndr 14 1889-94
[2]
Misra A(2018)Risk of infection in type 1 and type 2 diabetes compared with the General Population: a matched cohort study Diabetes Care 41 513-21
[3]
Carey IM(2021)Fluoroquinolone antibiotics and adverse events Aust Prescr 44 161-4
[4]
Critchley JA(2021)Fluoroquinolone Prescribing for Diabetic Foot Infections following an FDA Drug Safety Communication for aortic aneurysm risk Antimicrob Agents Chemother 65 e0070821-80
[5]
DeWilde S(2013)Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan Clin Infect Dis 57 971-90
[6]
Harris T(2022)Risk for hypoglycemic emergency with levofloxacin use, a population-based propensity score matched nested case-control study PLoS ONE 17 e0266471-5
[7]
Hosking FJ(2021)How safe are Fluoroquinolones for Diabetic Patients? A systematic review of Dysglycemic and Neuropathic Effects of Fluoroquinolones Ther Clin Risk Manag 17 1083-6
[8]
Cook DG(2013)The mechanisms of insulin secretion and calcium signaling in pancreatic β-cells exposed to fluoroquinolones Biol Pharm Bull 36 31-7
[9]
Baggio D(1996)Increase in insulin release from rat pancreatic islets by quinolone antibiotics Br J Pharmacol 117 372-5
[10]
Ananda-Rajah MR(2004)Effects of fluoroquinolones on insulin secretion and beta-cell ATP-sensitive K + channels Eur J Pharmacol 497 111-9